



维亚生物科技控股集团

VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

Stock Code: 1873

Viva Biotech 2026 Interim Results Conference

Date: August 27, 2026 (Thursday) Language: English

Forward-Looking Statements



Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, future events could turn out differently from those anticipated in such statements. There can be no assurance that forward-looking statements will prove to be accurate as such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause results and future events in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Accordingly, you are strongly cautioned not to place undue reliance on forward-looking statements. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date the Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws or listing rules.

Non-International Financial Reporting Standards

To supplement the Group’s unaudited consolidated financial statements which are presented in accordance with the International Financial Reporting Standards (“IFRS”), the Company has provided adjusted Non-IFRS net profit, adjusted Non-IFRS net profit margin, and adjusted Non-IFRS earnings per share as additional financial measures, which are not required by, or presented in accordance with, the IFRS. The Company believes that the adjusted Non-IFRS financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual and non-recurring items that the Group does not consider indicative of the performance of the Group’s business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the adjusted results on a stand-alone basis or as a substitute for results under the IFRS. The company provided detailed net profit to Non-IFRS net profit reconciliation in the appendix for reference.

A 3D molecular model of a protein complex, rendered in shades of teal and blue, set against a dark teal background with a light green diagonal stripe.

CONTENT

01 Business Highlights

02 Financial Performance

03 Future Strategies

Q&A Session



PART 1: Business Highlights

World Leading One-stop Innovative Original Drug R&D and Production Platform



CRO Business


Focus on FIC's Discover business, take SBDD as the core to drive FBDD, drug screening and drug design, and provide all biological and chemical services from Target to PCC

CDMO Research and Production Business


Provide innovative drug partners with small molecule CDMO, API, intermediates and formulation in the whole process of drug R&D and production

EFS Investment and Incubation Business

Focus on discovering and investing in high potential biotech start-ups to address unmet clinical medical needs




■ CRO ~ 405.1 million
■ CDMO Research and Production Business ~ 601.4 million



Note: Total Investment Value = Fair Value + Cash Returns


Equity Structure of Viva Biotech



- ◆ Up to now, Viva Group concentrates in three major sectors, holding 72.9% of the shares of Viva Biotech Shanghai, and wholly-holding Langhua Pharmaceutical and investment incubation.
- ◆ During the Reporting Period, the management of the Group and the Group's strategic investors carried out a number of collaborations with full mutual trust, giving full play to the advantages of strategic investors in global vision, capital markets and strategic resources, and enabling the Group to continuously improve in corporate governance, business operations, investment and financing, and strategic planning.

Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services

One-stop R&D Service Platform for Innovative Novel Drugs




New Molecular Modalities

- **PROTAC/Molecular Glue:** The Company have conducted research on 50+ E3 ligases and delivered 290+ ternary complexes of PROTAC. The molecular glue screening library has been scaled up to the ten-million level and targets a diverse range of E3 ligases.
- **Peptide Technology Platform:** Viva Biotech's AI-powered peptide drug design platform, Pep2MARSTM, has been fully launched. Integrated with diverse experimental technologies including DEL cyclic peptide libraries and phage display, the platform further bridges the entire drug discovery workflow — from computational design to molecular design, screening, and optimization. During the reporting period, multiple peer-reviewed articles related to the platform were successively published. The order structure has further shifted toward integrated dry-wet lab collaboration and full-package service contracts.
- **Antibody/Large Molecule R&D Technology Platform:** The platform validated Viva AIDD team's novel antibody discovery technology, marking the milestone of AI-driven de novo functional antibody design. In collaboration with the pharmacokinetics and pharmacodynamics departments, the platform has realized the capability to deliver end-to-end PCC services at Viva, from antibody discovery to PK/PD studies.
- **XDC Technology Platform:** The capabilities of the XDC platform have been further expanded. Based on molecular design, synthesis, and early-stage evaluation capabilities, metabolic and pharmacodynamic research capabilities for XDCs have been established, forming an end-to-end PCC service pipeline encompassing design, synthesis, characterization, metabolism, and pharmacodynamics.

Business Highlights

- Revenue in 2026H1 reached RMB**1006.5 million**, **+21.0%** YoY, **+25.1%** YoY on a constant exchange rate.
- Gross profit reached RMB**341.7 million**, **+0.7%** YoY, **+10.7%** YoY on a constant exchange rate.
- Gross profit margin: **34.0%**, **36.1%** on a constant exchange rate.
- Adjusted net profit reached RMB**128.3 million**, net profit reached RMB**100.9 million**, adjusted earnings per share (EPS) of **RMB0.05**, both representing a decline compared with the corresponding period of last year. **This was mainly attributable to the decrease in investment income contributions during the Reporting Period, unfavorable foreign exchange movements and increased R&D expenses associated with new business development.**
- As of the end of the period, the total number of clients in the Group stands at **2904**, **330** more than last year, widely distributed across North America, Europe, Asia, and other regions.
- Overseas revenue accounts for **84.8%** of the total.
- The total number of employees in the Group reaches **2213**.

RMB Million




Business Highlights



CRO Business: Revenue Growth Expected to Gradually Recover, Primarily Affected by Adverse Foreign-Exchange Movements in the Short Term

- Revenue: RMB**405.1 million**, **-4.2%** YoY, **-1.2%** YoY on a constant exchange rate.
- Adjusted gross profit: RMB**173.7 million**, **-10.7%** YoY, **-2.6%** YoY on a constant exchange rate.
- Adjusted gross profit margin:**42.9%**, gross profit margin **44.6%** on a constant exchange rate.
- Top 10 Customer Revenue Contribution: **26.6%**
- Revenue from Overseas: **87.1%**, **-1.8%** YoY
- Revenue from Mainland China: **12.9%**, **-17.7%** YoY, this was primarily attributable to the conclusion of a specific single project with a domestic client, excluding the impact of which, **+3.4% YoY**
- CFS Revenue: RMB**404.5 million**, SFE Revenue: RMB**0.6 million**
- Number of Independent Targets in 2026H1: **+212**
- Number of Protein Structures in 2026H1: **+9,278**
- **2026H1 new order YoY increased of 42.1%**
- New modalities (including peptides, antibodies, XDCs, PROTACs/molecular glues, etc.) accounted for approximately **17.7%** of CRO revenue, **+10.7%** YoY



CRO Business: R&D Headcount Steadily Recovering, With Client Base Continuing to Expand



R&D Headcount Steadily Recovering and Increasing



Number of CRO Clients: +18.9% YoY



Served Top 50 Global
Pharmaceutical Companies



Multiple clients of Viva Biotech are among the
15 most promising biotech companies listed in Fierce
Biotech's "Fierce 15" for 2025




CRO Business: AI Technology Facilitates the R&D of Novel Targets, Continuous Increase in Deliveries of Novel Targets and Protein Structures



AI Drives Continuous Growth in Delivered Novel Targets and Protein Structures




- Independent Target Research: **+212** YoY
- Accumulative Research: **2557**



- Protein Structure Deliveries Increase by **+9,278** YoY
- Cumulative Deliveries Reach **108,163** Cases



Synchrotron Radiation Source Utilization Efficiency Steadily Improving, Operating Hours Remaining Stable



- Maintaining long-term cooperation with **13** global synchrotron radiation source centers.
- Covering **10** countries and regions including Shanghai(China), the United States, Canada, Japan, Australia, the United Kingdom, France, Germany, Taiwan (China), and Switzerland, ensuring uninterrupted data collection throughout the year.

CRO Laboratories Area

- Shanghai: approx. 35,000 sq.m.
- Chengdu: approx. 10,800 sq.m.
- Jiaxing: approx. 5,335 sq.m.
- Suzhou: approx. 5,305 sq.m.


Shanghai Supercomputing Center

- The Shanghai Supercomputing Center is currently capable of supporting CADD calculations, AIDD computations, as well as computations for crystallography and cryo-electron microscopy groups.

Reserve Area

- Chengdu: There is still approximately **48,000 sq.m.** of property available for laboratory planning in the future.


AI Technology Driven Experiments Pave the Way for a New Era in Drug Development



[Talent Foundation → Technology Platform → Efficiency Breakthrough → Commercial Realization]

- ◆ **Versatile R&D Team:** Viva Biotech's interdisciplinary AI talent team boasts professional backgrounds spanning physics, chemistry, biology, pharmacy, and pharmaceutical engineering. Team members are graduates of top overseas universities as well as key domestic institutions (985/211 Project), demonstrating solid algorithmic expertise and extensive drug R&D experience.
- ◆ **Intellectual Property and Platform Development:** Established a dual-driven model of top-tier academic publications and core patent portfolios, with a focus on peptide generation, unnatural amino acid modifications, and diversified cyclization design. We have built an integrated platform combining computation and experimentation, along with the AIDD Web system, enabling precise translation from underlying algorithms to high-value commercial solutions.
- ◆ **Multi-Modal Technological Moat:** Leveraged multimodal proprietary algorithms to break through traditional chemical space limitations, enabling collaborative folding and precision design at the all-atom level. Prioritized cyclic peptide modality development while deepening expertise in small molecules and antibodies, thus establishing a technological moat encompassing a trillion-level library for screening and complex cyclization strategies and having delivered multiple cyclic peptide molecules with both high affinity and druggability.
- ◆ **Commercialization Milestones:** As of June 30, 2026, AIDD has engaged in **[228]** projects with **[92]** clients procured CADD/AIDD services. AI-enabled projects have contributed nearly **[14.0%]** of the total revenue of CRO business, and revenue from AI-client-related wet-lab services accounted for approximately **[15.0%]** of the Group's total CRO revenue. Moreover, the Company has established well-recognized collaborations in certain niche areas for integrated AI-enabled discovery solutions and has entered into strategic cooperation agreements with domestic pharmaceutical companies. Furthermore, the Company has entered into a deep collaboration with a global industry leader to jointly advance a new AI-driven “lab-in-the-loop” drug discovery model, which has been successfully and effectively validated.

MARS Enables Cross-Modality, End-to-End Drug Discovery




Target Discovery

Hit Identification

Lead Optimization

Drug Candidate


PCC



Mol2MARS

Small Molecules


- ✓ 300K+ Library for Virtual Screening & Hit Discovery
- ✓ Covalent Docking & Binder Design
- ✓ Allosteric Pocket Identification
- ✓ FEP-Based Binding Free Energy Prediction
- ✓ ADMET Prediction & Multi-Parameter Optimization



Pep2MARS

Peptide


- ✓ In-house Epitope Prediction Tools
- ✓ *De novo* Peptide Design
- ✓ In-House NCAA Library for Residue Substitution & Optimization
- ✓ Cyclization Optimization
- ✓ Automated Peptide Parameterization



Ab2MARS

Antibody

- ✓ Epitope Prediction & Antigen-Antibody Interface Analysis
- ✓ *De novo* Antibody Design
- ✓ Affinity Maturation & Key Residue Optimization
- ✓ Antibody Format Design & Conversion
- ✓ Patent busting & Differentiated Antibody Design



BiF2MARS

Bi-functionals

- ✓ Site-Specific Conjugation Design
- ✓ AI-Driven Linker Design & Optimization
- ✓ Complex Conformation & Spatial Geometry Assessment
- ✓ Aggregation Risk Prediction & Developability Optimization
- ✓ Payload Property Prediction & Multi-Parameter Optimization

Multi-Modality Platform



V-Sceptor
Core Algorithms




V-Orb
Physics Engine




V-Mantle
Data Hub

Pep2MARS—AI-Driven Peptide Drug Discovery Platform



CDMO R&D and Production Services


- Revenue of Langhua: **RMB601.4** million, **+47.0%** YoY, **+52.2%** YoY on a constant exchange rate.
- Adjusted gross profit of Langhua: **RMB175.1** million, **+12.9%** YoY, **+26.5%** YoY on a constant exchange rate.
- Adjusted gross profit margin of Langhua: **29.1%**, **+31.5%** YoY on a constant exchange rate.
- CDMO: Revenue **RMB 434.9** million, **+75.4% YoY**; adjusted gross profit margin **33.9%**;
- API (Business of generic drugs and active pharmaceutical ingredient): Revenue **RMB 126.0** million, **+23.5% YoY**; adjusted gross profit margin **16.7%**;
- Intermediates and formulation (Business of supply chain): Revenue **RMB 40.5** million, **-31.4% YoY**; adjusted gross profit margin **16.5%**;
- Number of Clients: **920**, **100%** client retention rate for top 10 clients;
- The factory of Langhua Pharmaceutical in Taizhou, Zhejiang has a GFA of approximately **40,936** square meters, and the Taizhou R&D center with an area of approximately **2,500** square meters. The R&D center and office in Ningbo have an area of approximately **2,513** square meters.



CDMO Business: Commercial Manufacturing Scale-Up Driving Revenue Growth and Capacity Construction Steadily Advance



CDMO Business: Entering a Phase of Accelerated Growth




- Revenue from CDMO: **RMB 434.9 million, +75.4% YoY**; Reasons for substantial revenue growth: The CDMO business of Langhua Pharmaceutical has two key new commercial projects. The **peptide project** has been successfully launched, with revenue ramping up to drive growth, while the **small-molecule project** is currently in PPQ stage.
- CDMO's **adjusted gross profit RMB 147.4 million, +20.3% YoY**; adjusted gross profit margin **33.9%**.
- As of now, Langhua Pharmaceutical's CDMO business has two key new commercial projects. The peptide project has been successfully commercialised, with revenue ramping up to drive growth, while the small-molecule project is currently in the PPQ stage and is expected to reach the market in 2027. Both projects are set to serve as key growth drivers for the CDMO business going forward.
- As of 2026H1, in respect of production capacity, our current available total capacity has reached **860 cubic meters**, which is sufficient to support the production needs of new commercialization projects over the next two years.
- Langhua Pharmaceutical is constructing an additional **400 cubic meters** of capacity to support the scaled-up production demand for new molecular modalities in the future. At present, internal installation work on certain production equipment and facilities has commenced in the new workshop, while technical upgrades in certain existing workshops are also underway in parallel, providing ample assurance for the capacity needs of commercial production. Furthermore, Langhua Pharmaceutical is also moving upstream along the industrial chain to further enhance the gross margin levels of its end products.


Optimized CMC Operations, Achieving a Turnaround from Loss to Profitability



Constant Increase in the Number of CMC Projects




The Overall CMC R&D Staff Remain Stable




Validated the Resource Funneling and Integrated Design within the Group

Customer Order Calculation



Customer Revenue Calculation



- The Group established a new **PPO business unit** and will continue to strengthen its technological capabilities in peptides, conjugated drugs, and small nucleic acids. The unit has already completed the build-out of peptide CMC-related capabilities and team assembly. During the Reporting Period, the PPO business unit delivered **21** projects accumulatively, with **19** projects currently in progress. Meanwhile, the **Taizhou plant has completed the design of its GMP peptide solid-phase synthesis production line and is about to commence installation work**, which will provide strong impetus for the continued growth of the peptide business.
- During the Reporting Period, through continuous optimization and refinement of its client structure, the Group's CMC business has steadily improved project delivery rates and client satisfaction, thereby successfully achieving a turnaround from loss to profitability.
- The AR882 pipeline of Arthroci, an incubation portfolio company of the Group, **has successfully secured PPQ-related service orders based on the new SOW signed between both parties, continuing to provide services for the Phase III clinical trials and subsequent commercial production of the AR882 project.**
- Since its inception, the CMC business has completed or is currently advancing a total of **320 new drug projects**, with R&D headcount reaching **107 personnel**.

EFS Investment & Incubation Business


- As the end of the reporting period, the Group has invested a total of **93** portfolio companies.
- During the reporting period, several portfolio companies achieved exits, generating aggregate cash proceeds of nearly RMB **218.4 million**.
- The portfolio companies have **232** pipelines, with **188** pipeline projects in preclinical stages and **44** pipelines in the clinical stage.
- **4** portfolio companies completed new round of financing, with a total exceeding **US\$250.0 million**.
- The investment income of approximately **RMB31.6 million** arising from changes in fair value during the Reporting Period was primarily **attributable to valuation increases in certain portfolio companies resulting from successful financing progress**.
- **Furthermore, Group may have several potential exits of our portfolio companies, which are expected to gradually receive cash returns and investment income in the next several years.**

Notes:

1. $Total\ investment\ value = Fair\ value + Cash\ received$

2. $Total\ cost = Total\ cash\ cost + Total\ EFS\ cost$

Source: Annual Results Announcements, 2025H1-2026H1 financial assets at FVTPL and interests in joint ventures and management's information






VBI Investment Exits and Components Overview



- As of 2026H1, VBI has invested in a total of 93 portfolio companies. The Group has successfully realized 19 investment exits or partial exits, and the enterprises invested in the incubation covered multiple indications, multiple molecular models and multiple regions around the world.
- As of 2026H1, the Company achieved investment exits from several incubation portfolio companies, successfully received cash of approx. RMB 218.4 million. Furthermore, the Company intends to use part of such exit proceeds to fully leverage its existing AI+SBDD dry and wet laboratory platform for incubation of the Group's proprietary pipelines.
- As of 2026H1, Viva Zongchen Biotech (Hangzhou) Co., Ltd. (a wholly-owned subsidiary of the Company), acting as a limited partner, participated in the establishment of and invested in a RMB-denominated fund, which has now commenced normal operations.

Exited Projects for the Reporting Period (Disclosure Based on Cash Proceeds Received)




Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress



232 Pipeline Projects in Portfolio Companies

*Calculated Based on the Cumulative Number of Portfolio Companies



- In 2026H1, **4** portfolio companies successfully raised new funding rounds, totaling approx. **US\$250.0 million**.
- **188 pipelines** are in pre-clinical stage, while **44 pipelines** have entered **clinical stage**.



- In May 2026, Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout.
- In May 2026, Full-Life Technologies announces US\$150 million financing to accelerate multiple clinical stage assets and manufacturing capabilities.
- In April 2026, TJ Biopharma entered into an agreement with Biogen for felzartamab assets in the Greater China region.
- In March 2026, the first patient for United InnoMed's NOVATRIA™ System was successfully enrolled in the clinical trial! The world's first RCT evaluating an implantable device for both heart failure therapy and monitoring has officially commenced.
- In March 2026, Iterion Therapeutics announced that the first patient was dosed in clinical trials of tegavivint for both colorectal cancer and relapsed/refractory osteosarcoma.
- In February 2026, Kainova Therapeutics announced positive Phase I results for DT-9081, an oral EP4 receptor antagonist, in advanced solid tumors, and secured \$32 million CAD in Series B financing.
- In February 2026, Grove Biopharma reported a preclinical study in *Nature Communications* demonstrating a novel approach to MYC and KRAS degradation.
- In February 2026, QurAlis demonstrated effects on disease progression and target engagement in the ANQR clinical trial of QRL-201, a first-in-class precision medicine in development for sporadic ALS.
- In February 2026, GenHouse Bio announced global partnership on its MAT2A inhibitor synthetic lethality therapy GH31 with Gilead.
- In January 2026, Genhouse Bio is pushing forward for its Hong Kong IPO, deepening its focus on the RAS signaling pathway and synthetic lethality to reshape the future of oncology through innovative drug discovery.
- In January 2026, QureBio Ltd. to present Phase II clinical trial results of its Q-1802 program at the 2026 ASCO Annual Meeting.
- In January 2026, ABM Therapeutics transferred the global rights of MEK inhibitor ABM-168 to Mosaica Medicines.

Key Projects in VBI Investment Portfolio



No.	Name	Country	Mechanism	Indication	Pipeline	Company Overview
1	Arthrosi	USA	Small Molecule	Gout and Tophus	Clinical Trial	A clinical-stage biotechnology company developing therapeutics for gout and chronic kidney disease. Its proprietary drug candidate, AR882, has demonstrated unprecedented potential for sustained uric acid lowering in gout patients and has the potential to develop additional therapies in clinical stages.
2	TJ Bio	CN	Large Molecule	Immunology	Clinical Trial	As a biopharmaceutical company integrating R&D, manufacturing, licensing, and product sales, it possesses clinical and commercial manufacturing facilities compliant with cGMP standards in China, the US, and the EU. Having completed a Series C1 financing of over RMB500 million following a restructuring with a Nasdaq-listed company, it integrates multiple projects in the clinical development pipeline, including long-acting growth hormone and CD38/CD73/CD47. The company is striving to become a leading player in China's innovative biologics sector.
3	VivaVision	CN	Small Molecule	Ophthalmology	Clinical Trial	This is a clinical-stage biotechnology company focused on innovative ophthalmic drug development. In addition to VVN001 for treating moderate-to-severe dry eye disease (currently in Phase III clinical trial), the company is developing VVN461 for non-infectious anterior uveitis and postoperative inflammation, and VVN539 for glaucoma or ocular hypertension. In January 2023, VivaVision partnered with Everads Therapy to develop innovative retinal disease therapies based on suprachoroidal drug delivery technology. The two parties will conduct preclinical studies together and plan to establish a joint venture in the future to advance commercialization.
4	Genhouse	CN	Small Molecule	Tumor	Clinical Trial	This is an innovative biopharmaceutical company specializing in the development of small-molecule anti-tumor drugs. In business development, Genhouse has established partnerships with multiple renowned companies and institutions. This includes an agreement with HUYABIO International for the out-licensing of overseas rights for the SHP2 project. In 2021, Genhouse entered into a strategic collaboration agreement with WuXi AppTec to jointly advance the R&D of its small-molecule anti-tumor drugs.
5	Haya	CH	LncRNA	Cardiovascular Disease, Metabolic Syndrome	Preclinical Trial	A precision medicine company focused on discovering and developing innovative tissue and cell-selective genomic drugs, its unique focus is RNA-guided programmable therapeutics that regulate the genome to address serious health problems including cardiovascular and metabolic diseases. In September 2024, Eli Lilly and Haya signed a multi-year collaboration agreement with a potential value of \$1 billion to use Haya's proprietary RNA-guided genomic platform to identify drug targets to address obesity and other chronic conditions.
6	Mediar	USA	Large Molecule	Immunology	Clinical Trial	A preclinical biotechnology company dedicated to developing therapies that can prevent or even reverse fibrosis. The platform and pipeline are based on an emerging new class of targets - fibrosis-mediating molecular drugs. These molecular drugs mainly play a key role in regulating the biology of myofibroblasts and the development of fibrosis in chronic damaged organs. In January 2025, Mediar reached a collaboration with Eli Lilly to advance WISP1, a first-in-class antibody for the treatment of idiopathic pulmonary fibrosis (IPF), with a potential payment of up to US\$786 million.
7	Basking	USA	Aptamer	Cardiovascular Disease	Clinical Trial	A clinical-stage company addressing the greatest need in ischemic stroke treatment - a rapid-onset, short-acting thrombolytic drug that can provide a significantly longer therapeutic window than existing therapies and reopen blocked arteries, with activity that can be rapidly reversed in the event of a bleed. The company's drug BB-031 is a first-in-class RNA aptamer that targets von Willebrand factor, an important structural component of blood clots and a driver of the coagulation process.
8	QurAlis	USA	Cell/Gene Therapy	Central nervous system	Clinical Trial	QurAlis, a US-based clinical-stage biotechnology company, is dedicated to developing precision therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Leveraging a proprietary human neuronal model, the company advances its pipeline of antisense oligonucleotide and small molecule programs targeting distinct disease subtypes. In June 2024, QurAlis entered into an agreement with Eli Lilly and Company in which QurAlis granted Lilly a license for an experimental drug candidate for ALS and frontotemporal dementia.
9	FuseBio	USA	Large Molecule	Tumor	Pre-clinical Trial	A biotechnology company focused on developing next-generation immunomodulatory therapies, dedicated to developing interleukin-18 (IL-18)-centric immunotherapies for cancer patients.
10	Proviva	CN	Large Molecule	Tumor	Clinical Trial	This is a clinical-stage biotechnology company founded in 2019. Leveraging its pro-cytokine fusion protein platform, Proviva is developing the bifunctional fusion protein PTX-912 (targeting IL-2R and PD-1) to treat solid tumors by controllably activating cytokines in the tumor microenvironment. The company initiated its first Phase I clinical trial in 2024.




PART 2: Financial Performance

Group Financial Performance: Solid Revenue & Net Profit Growth




Revenue of the Group Experienced a Significant YoY Increase




Note: under a constant exchange rate, the Group revenue +25.1% YoY

Group Gross Profit Experienced a YoY Increase




Note: under a constant exchange rate, the Group gross profit +10.7% YoY

Adjusted Non-IFRS Net Profit



Net Profit




CRO Financial Statistics: Primarily Impacted by Unfavorable Currency Movements, With Recovery Expected in 2026H2



CRO Revenue

RMB million



Note: under a constant exchange rate, CRO revenue -1.2% YoY

Adjusted Gross Profit


RMB million



Note: under a constant exchange rate, CRO adjusted gross profit -2.6% YoY

No. of CRO R&D personnel

Persons



Annual revenue per CRO R&D Personnel

RMB '000





CDMO Financial Statistics: Rapid Revenue Growth Driven by Ramp-Up of Commercial Products



Revenue and Adjusted Gross Profit of Langhua

RMB million

Langhua Adjusted Gross Margin Expected to Improve as the Industrial Chain Shifts Upstream Going Forward



Note: under a constant exchange rate, Langhua revenue +52.2% YoY, adjusted gross profit +26.5% YoY

Revenue Classifications of Principal Activities




As at June 30, 2026

	Drug discovery services	CDMO and commercialization service	VBI	Total
Types of goods or services	RMB'000	RMB'000	RMB'000	RMB'000
Revenue from non-investees				
Full-time-equivalent (FTE)	303,145	-	-	303,145
Fee-for-service (FFS)	95,111	11,528	-	106,619
Sale of products	-	560,610	-	560,618
Subtotal	398,256	572,138	-	970,394
Revenue from investees				
Full-time-equivalent (FTE)	4,069	-	-	4,069
Fee-for-service (FFS)	2,183	29,250	-	31,433
Service-for-equity service (SFE)	-	-	623	623
Subtotal	6,252	29,250	623	36,125
Revenue from Primary Business	404,508	601,388	623	1,006,519

Note: VBI refers to the CRO-related revenue generated from the service contracts signed between the relevant legal entities remained in the Group after the reorganization and the portfolio companies.

● Revenue Structure by Geographic Region of Primary Business



Items Measured at Fair Value with Changes in Fair Value Recognized in Profit or Loss



The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows :

	RMB'000
January 1, 2026	829,047
Recognized from SFE revenue	489
Gain on fair value change	31,577
Disposal	(13,294)
Exchange adjustment	(14,072)
At June 30, 2026	833,747
January 1, 2025	941,241
Acquired	9,713
Recognized from SFE revenue	535
Gain on fair value change	52,575
Disposal	(66,290)
Exchange adjustment	(2,025)
At June 30, 2025	935,749

● Accumulated Total Value from EFS Business

RMB million

	2025H1	2025	2026H1
Cash received	534.1	746.2	759.5
Fair value	935.7	829.0	833.7
Total investment value	1469.8	1575.2	1593.2

APPENDIX: Adjusted Non-IFRS Net Profit



	2026H1	2025FY	2025H1	2024FY	2024H1
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Net Profit / (Loss)	100,879	269,267	148,637	221,987	144,237
Add: Fair Value Gain on Financial Liabilities at FVTPL	-	-		-	
Add: interest expenses of the debt components of the Convertible Bonds		-		-	
Add: loss on repurchase of the Convertible Bonds		-		-	
Add: transaction costs of restructuring		-		1,836	
Add: non-recurring loss on disposal of fixed assets		-		-	
Add: amortization of acquired assets from acquisition	23,973	47,837	23,919	47,969	23,990
Add: foreign exchange loss		-		-	
Add: impairment losses on Property, Plant and Equipment		19,423	-	30,763	
Add: subsidiary's share incentive expenses	3,471	-1,224	10,912	12,057	
Adjusted Non-IFRS net profit	128,323	335,303	183,468	314,612	168,227
Adjusted Non-IFRS Net Profit Margin	12.7%	19.39%	22.1%	15.84%	17.10%



PART 3: Future Strategies


Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service Downstream



To Establish an Open and Cooperative Platform and a Win-win Ecosystem for Global Biopharmaceutical Innovators

- Raise technology barriers and expand servicing facilities and production capacity
- Strengthen talent acquisition and personnel incentives
- Advance business development worldwide
- Enhance continuity in CRO-CDMO business
- Strengthen the empowerment and driving role of AI in the original innovative drug R&D service platform
- Continuously bolster cross-diversion and synergy between biology & chemistry sectors

**Deepening strategic cooperation in the industry chain
Establish a one-stop service platform for global
innovative drug R&D and manufacturing**



A 3D molecular model of a protein complex, rendered in shades of blue and teal, positioned on the left side of the slide. The background features a dark teal shape on the left and a large, light gray stylized 'V' on the right.

Q&A Session



维亚生物科技控股集团

VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

Stock Code: 1873

Viva Biotech Holdings

No.735, Ziping Road, Pudong New
Area, Shanghai 201318, China

Tel: +86 21 6089 3288

E-mail: info@vivabiotech.com

www.vivabiotech.com